Effectiveness and safety of dabigatran compared to Vitamin K antagonists in non-asian patients with atrial fibrillation: a systematic review and meta-analysis
Abstract Background and Objective Real-life data about the use of dabigatran in patients
with non-valvular atrial fibrillation are warranted. The objective of this systematic review and …
with non-valvular atrial fibrillation are warranted. The objective of this systematic review and …
Dabigatran in real-world atrial fibrillation
J Carmo, FM Costa, J Ferreira… - Thrombosis and …, 2016 - thieme-connect.com
In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when
compared to warfarin. However, clinical trials are not very representative of the real-world …
compared to warfarin. However, clinical trials are not very representative of the real-world …
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
MV Huisman, C Teutsch, S Lu, HC Diener… - Clinical Research in …, 2022 - Springer
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …
[HTML][HTML] Comparative safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation: A network meta …
YH Chan, SW Chen, CY Chan, TF Chao - Journal of the Formosan Medical …, 2023 - Elsevier
Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs), with
a non-inferior or superior clinical efficacy profile compared to vitamin K antagonists (VKAs) …
a non-inferior or superior clinical efficacy profile compared to vitamin K antagonists (VKAs) …
Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings
W Darwiche… - International …, 2016 - internationaljournalofcardiology.com
Large randomized controlled trials have found that in non-valvular atrial fibrillation (AF), non-
vitamin K antagonist oral anticoagulants (NOACs) had a favorable risk–benefit profile, with …
vitamin K antagonist oral anticoagulants (NOACs) had a favorable risk–benefit profile, with …
Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis
RJ Romanelli, L Nolting, M Dolginsky… - … Quality and Outcomes, 2016 - Am Heart Assoc
Background—Trial data for the benefits and risks of dabigatran versus warfarin in the
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …
Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta …
PK Bundhun, N Chaudhary, J Yuan - BMC Cardiovascular Disorders, 2017 - Springer
Background The newer oral anticoagulant dabigatran is considered to be more beneficial in
patients with non-valvular Atrial Fibrillation (AF) when compared to warfarin. However …
patients with non-valvular Atrial Fibrillation (AF) when compared to warfarin. However …
Effectiveness and safety of dabigatran and warfarin in real‐world US patients with non‐valvular atrial fibrillation: a retrospective cohort study
JC Lauffenburger, JF Farley, AK Gehi… - Journal of the …, 2015 - Am Heart Assoc
Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran
Introduction: Nonvalvular atrial fibrillation (NVAF) is associated with a fivefold excess risk of
stroke. Antithrombotic therapy is crucial to reduce the risk of stroke. During past decades …
stroke. Antithrombotic therapy is crucial to reduce the risk of stroke. During past decades …
Comparative effectiveness and safety of dabigatran vs. warfarin in patients with atrial fibrillation-evidence from real world practice
M Avgil Tsadok, CA Jackevicius, V Essebag… - 2013 - Am Heart Assoc
Background: Dabigatran is a novel oral anticoagulant approved recently for stroke
prevention in atrial fibrillation (AF) in North America. We aimed to assess the effectiveness …
prevention in atrial fibrillation (AF) in North America. We aimed to assess the effectiveness …
相关搜索
- atrial fibrillation meta analysis
- atrial fibrillation safety of dabigatran
- atrial fibrillation clinical practice
- meta analysis dabigatran in patients
- meta analysis effectiveness and safety
- warfarin in patients safety of dabigatran
- real world safety of dabigatran
- atrial fibrillation bleeding risk
- low dose dabigatran in patients
- atrial fibrillation low dose
- atrial fibrillation real world
- meta analysis bleeding risk
- meta analysis low dose
- bleeding events dabigatran in patients
- atrial fibrillation old concerns
- atrial fibrillation oral anticoagulation